A Double-Blind Placebo-Controlled Phase II Study to Determine the Efficacy, Safety, Tolerability and Pharmacokinetics of a Controlled Release (CR) Formulation of Mazindol in Adults With DSM-5 Attention Deficit Hyperactivity Disorder (ADHD)

Trial Profile

A Double-Blind Placebo-Controlled Phase II Study to Determine the Efficacy, Safety, Tolerability and Pharmacokinetics of a Controlled Release (CR) Formulation of Mazindol in Adults With DSM-5 Attention Deficit Hyperactivity Disorder (ADHD)

Completed
Phase of Trial: Phase II

Latest Information Update: 31 May 2017

At a glance

  • Drugs Mazindol (Primary)
  • Indications Attention-deficit hyperactivity disorder
  • Focus Proof of concept; Therapeutic Use
  • Sponsors NLS Pharma
  • Most Recent Events

    • 31 May 2017 Results (n= 85) from this study published in a NLS Pharma Media Release.
    • 16 May 2017 According to a NLS Pharma media release, Full results will be presented in upcoming conference on May 30, 2017 in Miami.
    • 16 May 2017 According to a NLS Pharma media release, primary endpoint has been met. (ADHD Rating Scale)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top